Neoadjuvant Therapy for Men with High Risk Disease Prior to Prostatectomy - Mary-Ellen Taplin
February 23, 2018
Mary-Ellen Taplin, MD, and Alicia Morgans, MD discuss the topic of neoadjuvant therapy for men with high-risk disease prior to surgery, specifically, prior to prostatectomy. Among the topics discussed include the importance of studying neoadjuvant chemotherapy and hormonal therapies in clinical trials before being used more broadly in everyday clinical practice, patient selection, and Mary-Ellen’s 2018 ASCO GU talk “Newly Diagnosed High-Risk Disease Treatment: Summarizing Neoadjuvant Trials”.
They briefly discuss the ICECaP study Mary-Ellen completed with Rana McKay on testosterone recovery after androgen deprivation therapy. They also highlight the PUNCH trial which is scheduled to conclude later in 2018. This will be the only phase III clinical trial in the current era which will show the outcomes of neoadjuvant treatment prior to prostatectomy and is the last large phase III trial, in high risk localized prostate cancer, which started 11 years ago.
Mary-Ellen Taplin, MD is a medical oncologist in Boston, Massachusetts and is affiliated with multiple hospitals in the area, including Brigham and Women's Hospital and Dana-Farber Cancer Institute. She received her medical degree from University of Massachusetts Medical School and has been in practice for more than 20 years. She completed a residency in internal medicine and chief residency at the University of Massachusetts Medical Center and an oncology-hematology fellowship at Beth Israel Hospital and Harvard Medical School.
Dr. Taplin was on staff in medical oncology-hematology as an assistant and then associate professor of medicine at the University of Massachusetts from 1993 to 2003, when she joined Dana-Farber Cancer Institute.
Alicia Morgans, MD, MPH
Further Related Content:
A Presentation by Mary-Ellen Taplin at the 2018 ASCO GU Meeting: Newly Diagnosed High-Risk Disease Treatment: Summarizing Neoadjuvant Trials
Watch: Over-treatment in the Name of Cure: Revisiting Adjuvant Therapy in the Modern Era? - Christopher Sweeney
Newly Diagnosed High-Risk Disease Treatment: Summarizing Neoadjuvant Trials
Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer - Abstract
The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP)
Chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer: Long-term follow-up of a phase II trial, "Beyond the Abstract," by Mari Nakabayashi, MD, PhD and Mary-Ellen Taplin, MD
AUA Guidelines 2017 – localized, high risk prostate cancer